Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Venezia Rocco | Chief Accounting Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 14,669 | $19.00 | $278,711 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Venezia Rocco | Chief Accounting Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 10,782 | $19.00 | $204,858 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Freedberg Jared | General Counsel | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 33,762 | $19.00 | $641,478 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Freedberg Jared | General Counsel | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 22,681 | $19.00 | $430,939 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Miller-Rich Nancy | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Miller-Rich Nancy | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 22,304 | $19.00 | $423,776 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Richardson Linda M | EVP & Chief Commercial Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 26,585 | $19.00 | $505,115 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Richardson Linda M | EVP & Chief Commercial Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 16,706 | $19.00 | $317,414 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| AKKARAJU SRINIVAS | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| AKKARAJU SRINIVAS | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 640,688 | $19.00 | $12,173,072 | 0Indirect | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| AKKARAJU SRINIVAS | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 37,887 | $19.00 | $719,853 | 0Direct, See footnote | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Fundaro Paolo | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Fundaro Paolo | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 35,794 | $19.00 | $680,086 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| SBLENDORIO GLENN | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| SBLENDORIO GLENN | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 23,447 | $19.00 | $445,493 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Gottesdiener Keith Michael | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Gottesdiener Keith Michael | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 24,719 | $19.00 | $469,661 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| BRADBURY DANIEL | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 8,111 | $19.00 | $154,109 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| BRADBURY DANIEL | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 7,812 | $19.00 | $148,428 | 0Indirect | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| BRADBURY DANIEL | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 23,548 | $19.00 | $447,412 | 0Direct, See footnote | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Saik Andrew | EVP & Chief Financial Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 45,244 | $19.00 | $859,636 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Saik Andrew | EVP & Chief Financial Officer | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 23,021 | $19.00 | $437,399 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Pruzanski Mark | Director | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 618,894 | $19.00 | $11,758,986 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Berrey M Michelle | President, R&D and CMO | INTERCEPT PHARMACEUTICALS, INC. | OtherD · Sale or transfer back to the company | 51,790 | $19.00 | $984,010 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 | |
| Berrey M Michelle | President, R&D and CMO | INTERCEPT PHARMACEUTICALS, INC. | OtherU · Shares tendered in a change of control | 28,349 | $19.00 | $538,631 | 0Direct | Form 4 filed 13 Nov 2023, on sec.gov (opens in a new tab)Filed 13 Nov 2023 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.